(PDF) Disease-Modifying Drugs for Relapsing-Remitting

Disease-Modifying Drugs for Relapsing-Remitting Multiple Sclerosis and Future Directions for Multiple Sclerosis Therapeutics

Archives of Neurology

doi 10.1001/archneur.56.9.1079

Full Text

Abstract

Available in full text

Date

September 1, 1999

Authors

Richard A. Rudick

Publisher

American Medical Association (AMA)

Related search

Disease-Modifying Therapies in Relapsing–remitting Multiple Sclerosis

Neuropsychiatric Disease and Treatment

Biological Psychiatry

English

Comparing the Cost-Effectiveness of Disease-Modifying Drugs for the First-Line Treatment of Relapsing-Remitting Multiple Sclerosis

Journal of Managed Care Pharmacy

English

Characteristics of Pediatric Patients With Relapsing Remitting Multiple Sclerosis Taking Disease Modifying Agents

Value in Health

Occupational Health

English

Cerebrovascular Reactivity and Disease Activity in Relapsing-Remitting Multiple Sclerosis

Advances in Clinical and Experimental Medicine

Molecular Biology

English

Intestinal Permeability in Relapsing-Remitting Multiple Sclerosis

Neurotherapeutics

English

Natalizumab: A New Treatment for Relapsing Remitting Multiple Sclerosis

Therapeutics and Clinical Risk Management

Chemical Health

Safety Research

English

Progressive Multifocal Leukoencephalopathy and Relapsing-Remitting Multiple Sclerosis

Archives of Neurology

English

Alemtuzumab: Evidence for Its Potential in Relapsing–remitting Multiple Sclerosis

Drug Design, Development and Therapy

Pharmaceutical Science

English

Descriptive Evalaution of Characteristics of Patients Diagnosed With Relapsing Remitting Multiple Sclerosis and Taking Disease Modifying Agents

Value in Health

Occupational Health

English